MBIO - Mustang announces positive data from gene therapy trial to treat X-linked immunodeficiency

Mustang Bio (NASDAQ:MBIO) said on Thursday treatment with its lentiviral gene therapy, MB-107, for X-linked severe combined immunodeficiency (XSCID) in newly diagnosed infants under the age of two support plans to begin a Phase 2 trial in the second half of this year. The data includes 23 infants with XSCID therapy at a median age of 3 months, with a median follow-up of 2.6 years. The company said the treatment was well tolerated, and all patients experienced complete hematopoietic recovery. Seventeen patients had active infections prior to therapy, and in all cases the infections cleared. The lentiviral gene therapy is also being assessed in a Phase 1/2 clinical trial at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Patients with XSCID have no T-cells or natural killer (NK) cells. These patients are usually affected by severe bacterial, viral or fungal infections early in life and often

For further details see:

Mustang announces positive data from gene therapy trial to treat X-linked immunodeficiency